Show simple item record

dc.contributor.authorAkone, Sergi Herve
dc.contributor.authorNtie-Kang, Fidele
dc.contributor.authorStuhldreier, Fabian
dc.contributor.authorEwonkem, Monique Bassomo
dc.contributor.authorNoah, Alexandre Mboene
dc.contributor.authorMouelle, Simon Eitel Misse
dc.contributor.authorMüller, Rolf
dc.date.accessioned2020-09-24T11:38:14Z
dc.date.available2020-09-24T11:38:14Z
dc.date.issued2020-08-13
dc.identifier.citationFront Pharmacol. 2020 Aug 13;11:992. doi: 10.3389/fphar.2020.00992. PMID: 32903500; PMCID: PMC7438611.en_US
dc.identifier.issn1663-9812
dc.identifier.pmid32903500
dc.identifier.doi10.3389/fphar.2020.00992
dc.identifier.urihttp://hdl.handle.net/10033/622450
dc.description.abstractEpigenetics refers to heritable changes in gene expression and chromatin structure without change in a DNA sequence. Several epigenetic modifications and respective regulators have been reported. These include DNA methylation, chromatin remodeling, histone post-translational modifications, and non-coding RNAs. Emerging evidence has revealed that epigenetic dysregulations are involved in a wide range of diseases including cancers. Therefore, the reversible nature of epigenetic modifications concerning activation or inhibition of enzymes involved could be promising targets and useful tools for the elucidation of cellular and biological phenomena. In this review, emphasis is laid on natural products that inhibit DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) making them promising candidates for the development of lead structures for anticancer-drugs targeting epigenetic modifications. However, most of the natural products targeting HDAC and/or DNMT lack isoform selectivity, which is important for determining their potential use as therapeutic agents. Nevertheless, the structures presented in this review offer the well-founded basis that screening and chemical modifications of natural products will in future provide not only leads to the identification of more specific inhibitors with fewer side effects, but also important features for the elucidation of HDAC and DNMT function with respect to cancer treatment.en_US
dc.language.isoenen_US
dc.publisherFrontiersen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectDNA methyltransferasesen_US
dc.subjectcanceren_US
dc.subjectepigeneticsen_US
dc.subjecthistone deacetylasesen_US
dc.subjectinhibitionen_US
dc.subjectnatural productsen_US
dc.titleNatural Products Impacting DNA Methyltransferases and Histone Deacetylases.en_US
dc.typeReviewen_US
dc.typeOtheren_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalFrontiers in pharmacologyen_US
dc.source.volume11
dc.source.beginpage992
dc.source.endpage
refterms.dateFOA2020-09-24T11:38:15Z
dc.source.journaltitleFrontiers in pharmacology
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Akone et al.pdf
Size:
1.921Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International